文献速递药物不良反应与药物警戒

MCSG:一种在大规模药物警戒数据库中同时进行失衡分析与背景率估计的方法

MCSG: A Method for Simultaneous Disproportionality Analysis and Background Rate Estimation in Large Pharmacovigilance Databases.
PubMed 文献 · Drug Saf · 2025-12-06

研究提出分层贝叶斯模型与MCMC迭代算法MCSG,同时估计药物-不良事件对的背景率并检测显著偏离的计数,以克服 masking 效应。在含强masking的合成数据和含69种活性物质、792个不良事件的参考集上,MCSG优于常规定量信号检测方法,并在FAERS部分真实数据中识别出阳性与阴性对照及文献提示的药物-不良事件对。

要点

  • MCSG可同时估计背景率并检测偏离背景率的药物-不良事件对。
  • 在含强masking效应的合成数据中,MCSG准确识别了偏离恒定背景率的选定药物-不良事件对。
  • MCSG适用于不频繁的大规模分析,如对全库的季度分析。

核心结论

  • MCSG提供了一种新的信号生成方法,较现有方法更有效地避免masking的混杂效应。
  • 该算法最适用于多个药物-不良事件对中大多数预期处于背景率计数的场景。
  • 在大规模数据集上算法运行可能需要数分钟至数小时,适合不频繁的大规模分析。

研究设计与样本

  • 构建分层贝叶斯背景率模型,采用迭代MCMC方法从模型参数抽取背景率样本。
  • 每次迭代剔除在当前背景率估计下概率低的计数,再采样下一组背景率。
  • 算法以Python与概率编程语言Stan联合实现,称为马尔可夫链信号生成(MCSG)。

主要发现

  • 在特意包含具有非常强masking效应的药物-不良事件对的合成数据上,MCSG优于常规定量信号检测方法。
  • 在含69种独特活性物质和792个独特不良事件的参考集上,MCSG同样优于常规定量方法。
  • 在偏离恒定背景率的合成数据集上,MCSG在存在强masking信号时准确识别了这些对。
  • 在FAERS部分真实数据子集上,MCSG有效识别了阳性与阴性对照参考集,并能识别文献中提示的药物-不良事件对。

临床怎么用

  • 可用于药物警戒数据库的全库季度性大规模信号筛查,尤其关注masking可能掩盖的信号。
  • 解读时需注意算法适用于大多数药物-不良事件对处于背景率的场景。
  • 大规模数据运行耗时较长,宜安排为不频繁的批量分析而非实时检测。

局限性

  • 原文未在摘要中报告具体阈值、剂量或P值等定量判定标准。
  • 算法在大规模数据集上运行可能需数分钟至数小时,不适合实时分析。
  • 摘要仅提及FAERS部分真实数据子集的结果,未报告全库验证情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Databases for safety monitoring of medicinal products contain records of a huge number of pairings of drugs and adverse events (AEs). Existing disproportionality methods for safety monitoring in such databases estimate background rates of AE occurrence in ways that may be susceptible to masking effects that can hinder signal detection, particularly in the context of large overall counts of AE or drug occurrence in the data. OBJECTIVES: To develop a new statistical model for determining the background rate against which individual drug-AE pairs are to be evaluated, which is robust against masking effects, and to incorporate this into an algorithm which simultaneously estimates background rates and detects drug-AE pair counts that deviate significantly from these rates. METHODS: We constructed a hierarchical Bayesian model for background rates, and background rate samples were drawn from the model parameters using an iterative Markov Chain Monte Carlo (MCMC) method. At each iteration, any counts whose probability is low given current background rate estimation were removed from the computation that sampled the next set of background rates. The algorithm, called Markov Chain Signal Generation (MCSG), was implemented using a combination of Python and the probabilistic programming language Stan. RESULTS: The MCSG algorithm outperformed routinely used quantitative approaches for signal detection on both synthetic data designed to include a drug-AE pair with very strong masking effects and a reference set featuring 69 unique active substances and 792 unique AEs. On a synthetic dataset where selected pairs occurred at rates deviating from a constant background, MCSG accurately identified these pairs in the presence of strong masking signals. On a subset of some real data from the FDA Adverse Event Report System (FAERS), it effectively identified a reference set of positive and negative controls and was able to identify drug-AE pairs suggested in the literature. CONCLUSION: We have demonstrated a new approach to signal generation, which avoids the confounding effect of masking more effectively than currently used methods. The algorithm is best used in a setting of multiple drug-AE pairs, the majority of which are expected to have counts at background rate, although with substantial datasets the algorithm can take minutes or hours to run. It is therefore particularly suitable for infrequent, large-scale analysis (for example, quarterly analysis of the entirety of a pharmacovigilance database).

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Bright M, Kontsioti E, Pirmohamed M, et al. MCSG: A Method for Simultaneous Disproportionality Analysis and Background Rate Estimation in Large Pharmacovigilance Databases. Drug Saf. 2025. PMID: 41351764. doi:10.1007/s40264-025-01632-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。